Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

ANSLUTER till LungCare

5 november 2026 uppdaterad av: University of California, San Francisco

This study evaluates a smoking cessation intervention (CONNECTing to LungCare) for improving shared decision-making conversations about smoking cessation and lung cancer screening between patients and providers. Shared decision making is a patient care model in which providers offer information regarding risks and benefits, patients express their values and preferences, and then healthcare decisions are jointly discussed between the patient and provider. Patient education, aided by decision support tools, can increase patients' knowledge, decrease their decisional conflict, promote decision making, and improve the patients' perception of risk. CONNECTing to LungCare is an interactive education intervention that addresses lung cancer screening and smoking cessation and provides participants with a tailored summary that may make them more likely to have shared decision-making discussions with their providers about smoking cessation and lung cancer screening.

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVES:

Aim 1: Development of the smoking cessation and LCS intervention, CONNECTing to LungCare.

Aim 2: Test CONNECTing to Lung Care for Feasibility and Acceptability (N=120)

Aim 3: To qualitatively evaluate feasibility and acceptability of the intervention and study procedures from the perspectives of patients, providers, staff and administrators and other stakeholders.

OUTLINE:

BETA TESTING: Participants interact with the CONNECTing to LungCare intervention and provide feedback in support of intervention refinement.

FEASIBILITY TRIAL: Participants are randomized to 1 of 2 groups.

GROUP I: Participants receive the CONNECTing to LungCare intervention, including education about the benefits and risks of LCS and the importance of shared decision making, computerized assessments of the participant's smoking status, readiness to quit and concerns about quitting, and video segments tailored to the participant's responses to assessment questions, prior to their primary care appointment. Participants and their providers receive a tailored summary of the participant's concerns and barriers to quitting to enhance motivation for smoking cessation and shared decision making discussions. Participants then receive up to 3 follow-up phone calls over 10-15 minutes each encouraging them to follow up with their provider, to complete the shared decision-making conversation, obtain LCS if appropriate, and access smoking cessation resources. Participants may also receive brief, tailored follow-up text messages that include links to video segments or cessation resources 1-3 times weekly.

GROUP II: Participants receive usual care from their provider at their primary care appointment.

After completion of study intervention, participants are followed up at 1 and 3 months.

Studietyp

Interventionell

Inskrivning (Faktisk)

53

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • San Francisco, California, Förenta staterna, 94143
        • University of California, San Francisco

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • English, Spanish and Cantonese speaking
  • Age >= 18 years old
  • Primary care patients at the University of California, San Francisco (UCSF) General Internal Medicine (GIM) clinics
  • Must be current smokers and/or candidates for Lung Cancer Screening (LCS).

Key Informant Interviews:

- Must be working in one of the clinics participating in CONNECTing to LungCare.

Exclusion Criteria:

  • Not a current smoker

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Övrig: Beta testing (CONNECTing to LungCare, feedback)

Participants interact with the CONNECTing to LungCare intervention and provide feedback in support of intervention refinement.

Ancillary studies

Multimedia program administered either remotely or in person

Andra namn:
  • ANSLUTER till LungCare intervention
Experimentell: Feasibility trial, Group I (CONNECTing to LungCare)

Participants receive the CONNECTing to LungCare intervention, including education about the benefits and risks of LCS and the importance of shared decision making, computerized assessments of the participant's smoking status, readiness to quit and concerns about quitting, and video segments tailored to the participant's responses to assessment questions, prior to their primary care appointment. Participants and their providers receive a tailored summary of the participant's concerns and barriers to quitting to enhance motivation for smoking cessation and shared decision-making discussions. Participants then receive up to 3 follow-up phone calls over 10-15 minutes each encouraging them to follow up with their provider, to complete the shared decision-making conversation, obtain LCS if appropriate, and access smoking cessation resources. Participants may also receive brief, tailored follow-up text messages that include links to video segments or cessation resources 1-3 times weekly.

Ancillary studies

Multimedia program administered either remotely or in person

Andra namn:
  • ANSLUTER till LungCare intervention

Saliva samples will be collected from each participant

Andra namn:
  • Bioprovsamling
  • Provprov
  • Salivprov
Aktiv komparator: Feasibility trial, Group II (usual care)

Participants receive usual care from their provider at their primary care appointment.

Ancillary studies

Multimedia program administered either remotely or in person

Andra namn:
  • ANSLUTER till LungCare intervention

Saliva samples will be collected from each participant

Andra namn:
  • Bioprovsamling
  • Provprov
  • Salivprov

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Recruitment rate
Tidsram: Up to 1 year

The percentage of participants who were contacted and joined the study will be reported.

Up to 1 year
Retention rates
Tidsram: Up to 1 year

The percentage of participants who joined the study and completed the program will be reported.

Up to 1 year
Adherence rates
Tidsram: Up to 1 year

The percentage of participants who joined the study and completed all tasks within the program will be reported.

Up to 1 year
Overall time required to recruit to the target sample size (Feasibility Cohort)
Tidsram: Up to 1 year

The overall time in weeks required to recruit participants for the feasibility cohort will be reported.

Up to 1 year
Number of eligible participants
Tidsram: Up to 1 year

The number of eligible participants required to recruit the required sample size will be reported

Up to 1 year

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Smoking cessation rates
Tidsram: At 3 months

Will evaluate the impact of the intervention on smoking cessation rates. Rates of smoking cessation will be measured by self-report and validated by salivary cotinine levels.

At 3 months
Lung cancer screening (LCS) rates
Tidsram: Up to 3 months

Rates of LCS will be evaluated through review of the electronic health record (EHR)

Up to 3 months
Shared decision making about LCS
Tidsram: Up to 3 months

Evidence of shared decision-making conversation will be obtained through one week follow up phone call and with review of the EHR three months after the primary care physician visit.

Up to 3 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Judith Walsh-Cassidy, MD, University of California, San Francisco

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 december 2024

Primärt slutförande (Beräknad)

30 september 2027

Avslutad studie (Beräknad)

30 september 2027

Studieregistreringsdatum

Först inskickad

9 januari 2024

Först inskickad som uppfyllde QC-kriterierna

9 januari 2024

Första postat (Faktisk)

19 januari 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 226311
  • NCI-2023-10506 (Registeridentifierare: NCI Clinical Trials Reporting Program (CTRP))

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera